NCT03364998View on ClinicalTrials.gov

BAY94-9027 PK Study Comparing to Another Long Acting Product

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

January 25, 2018

Study Completion Date

September 28, 2018

Conditions
Hemophilia A
Interventions
DRUG

Damoctocog (Jivi, BAY94-9027)

60 international units (IU)/kg, given as a 10 minute injection, 1 dose

DRUG

Elocta

60 IU/kg, given as a 10 minute injection, 1 dose

Trial Locations (1)

1756

SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03364998 - BAY94-9027 PK Study Comparing to Another Long Acting Product | Biotech Hunter | Biotech Hunter